Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...
Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...
(RTTNews) - Gilead Sciences Inc. (GILD) announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of ...
Gilead Sciences, Inc. today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's ...
Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured ...
Trump’s newly named WH chief of staff Susie Wiles retained her position as co-chair of the lobbying firm Mercury Public ...
MarketBeat on MSN6d
Gilead's Stock Surge: What's Fueling the Momentum?Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...
Investor's Business Daily on MSN6d
Gilead Sciences Easily Beats Third-Quarter Views Driven By Solid Biktarvy SalesGilead Sciences easily beat third-quarter forecasts late Wednesday, and raised its outlook in a move that could bolster ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback